Summit Therapeutics Inc. Other Operating Income (Expense), Net
Summit Therapeutics Inc. (SMMT) reported Other Operating Income (Expense), Net of $313.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherOperatingIncomeExpenseNet · last filed 2025-02-24
- Summit Therapeutics Inc. other operating income (expense), net for the quarter ending 2024-12-31 was $205.00K, a 14.53% increase year-over-year.
- Summit Therapeutics Inc. other operating income (expense), net for the quarter ending 2024-09-30 was -$264.00K, a 199.62% decline year-over-year.
- Summit Therapeutics Inc. other operating income (expense), net for the quarter ending 2024-06-30 was $159.00K.
- Summit Therapeutics Inc. other operating income (expense), net for the quarter ending 2024-03-31 was $213.00K, a 63.53% decline year-over-year.
- Summit Therapeutics Inc. other operating income (expense), net for fiscal 2024 was $313.00K, a 68.73% decline from fiscal 2023.
- Summit Therapeutics Inc. other operating income (expense), net for fiscal 2023 was $1.00M, a 93.06% decline from fiscal 2022.
- Summit Therapeutics Inc. other operating income (expense), net for fiscal 2022 was $14.42M.
| Period end | Other Operating Income (Expense), Net 3 month | Other Operating Income (Expense), Net 6 month | Other Operating Income (Expense), Net 9 month | Other Operating Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2024-12-31 | $205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$59.00K derived: sum of 2 quarters · filed 2025-02-24 | $100.00K derived: sum of 3 quarters · filed 2025-02-24 | $313.00K 10-K · filed 2025-02-24 |
| 2024-09-30 | -$264.00K 10-Q · filed 2024-10-30 | -$105.00K derived: sum of 2 quarters · filed 2024-10-30 | $108.00K 10-Q · filed 2024-10-30 | $287.00K derived: sum of 4 quarters · filed 2025-02-24 |
| 2024-06-30 | $159.00K 10-Q · filed 2024-08-06 | $372.00K 10-Q · filed 2024-08-06 | $551.00K derived: sum of 3 quarters · filed 2025-02-24 | $816.00K derived: sum of 4 quarters · filed 2025-02-24 |
| 2024-03-31 | $213.00K 10-Q · filed 2024-05-01 | $392.00K derived: sum of 2 quarters · filed 2025-02-24 | $657.00K derived: sum of 3 quarters · filed 2025-02-24 | $630.00K derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $444.00K derived: sum of 2 quarters · filed 2025-02-24 | $417.00K derived: sum of 3 quarters · filed 2025-02-24 | $1.00M 10-K · filed 2025-02-24 |
| 2023-09-30 | $265.00K 10-Q · filed 2024-10-30 | $238.00K derived: sum of 2 quarters · filed 2024-10-30 | $822.00K 10-Q · filed 2024-10-30 | $1.96M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-06-30 | -$27.00K 10-Q · filed 2024-08-06 | $557.00K 10-Q · filed 2024-08-06 | $1.69M derived: sum of 3 quarters · filed 2025-02-24 | $7.15M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-03-31 | $584.00K 10-Q · filed 2024-05-01 | $1.72M derived: sum of 2 quarters · filed 2025-02-24 | $7.18M derived: sum of 3 quarters · filed 2025-02-24 | $10.19M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $6.59M derived: sum of 2 quarters · filed 2025-02-24 | $9.61M derived: sum of 3 quarters · filed 2025-02-24 | $14.42M 10-K · filed 2025-02-24 |
| 2022-09-30 | $5.46M 10-Q · filed 2023-11-07 | $8.48M derived: sum of 2 quarters · filed 2023-11-07 | $13.28M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $3.01M 10-Q · filed 2023-08-09 | $7.82M 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |